ATF2 and head and neck squamous cell carcinoma: Cytoplasmic accumulation of ATF-2 and altered mitochondrial membrane potential have been shown to enhance the sensitivity of cancer cells to cytotoxic agents and radiation [33, 36–38], leading us to hypothesize that rigosertib could act synergistically in combination with HNSCC standard-of-care therapies.